Literature DB >> 27981684

Gastrointestinal symptom severity in irritable bowel syndrome, inflammatory bowel disease and the general population.

A D Lee1,2,3,4,5, B M Spiegel1,2,4,6,7, R D Hays3,7,8, G Y Melmed1, R Bolus4,6, D Khanna9, P P Khanna9, L Chang6,10.   

Abstract

BACKGROUND: Irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) patients report similar gastrointestinal (GI) symptoms, yet comparisons of symptom severity between groups and with the general population (GP) are lacking.
METHODS: We compared Patient-Reported Outcomes Measurement Information System (PROMIS® ) GI symptom scales measuring gastro-esophageal reflux (GER), disrupted swallowing, diarrhea, bowel incontinence, nausea/vomiting, constipation, belly pain, and gas/bloating in: (i) USA GP sample, (ii) IBS patients, and (iii) IBD patients from tertiary care and community populations. Symptom severity scores were based on T-score metric with mean 50±10 (standard deviation) relative to the GP. KEY
RESULTS: Of 1643 patients enrolled, there were 253 IBS patients (68% F, mean age 45±15 years), 213 IBD patients (46% F, mean age 41±14 years), and 1177 GP subjects (57% F, mean age 46±16 years). IBS patients reported greater severity of GER, disrupted swallowing, nausea/vomiting, belly pain, gas/bloating, and constipation symptoms than their IBD counterparts (all P<.05). Compared to the GP, IBD patients had worse belly pain, gas/bloating, diarrhea, and bowel incontinence, but less severe GER and disrupted swallowing (all P<.05), and IBS patients had more severe nausea/vomiting, belly pain, gas/bloating, and constipation (all P<.05). Women had more severe belly pain and gas/bloating than men, whereas men had more severe bowel incontinence (all P<.05). CONCLUSION & INFERENCES: IBS and IBD are associated with more severe GI symptoms compared to the GP excluding esophageal symptoms. Unlike IBD, IBS is not characterized by observable GI inflammation but patients report more severe upper and lower GI symptoms.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  gender; inflammatory bowel disease; irritable bowel syndrome; symptom severity

Mesh:

Year:  2016        PMID: 27981684      PMCID: PMC5393974          DOI: 10.1111/nmo.13003

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  52 in total

Review 1.  Epidemiology of gastro-oesophageal reflux disease: a systematic review.

Authors:  J Dent; H B El-Serag; M-A Wallander; S Johansson
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

Review 2.  The illness experience: state of knowledge and perspectives for research.

Authors:  Janine Pierret
Journal:  Sociol Health Illn       Date:  2003

3.  Inflammatory bowel disease, irritable bowel syndrome, or what?: A challenge to the functional-organic dichotomy.

Authors:  Millie D Long; Douglas A Drossman
Journal:  Am J Gastroenterol       Date:  2010-08       Impact factor: 10.864

Review 4.  Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis.

Authors:  Rebecca M Lovell; Alexander C Ford
Journal:  Am J Gastroenterol       Date:  2012-05-22       Impact factor: 10.864

5.  Evidence for two distinct perceptual alterations in irritable bowel syndrome.

Authors:  B D Naliboff; J Munakata; S Fullerton; R H Gracely; A Kodner; F Harraf; E A Mayer
Journal:  Gut       Date:  1997-10       Impact factor: 23.059

6.  Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome.

Authors:  Michael J Sydora; Beate C Sydora; Richard N Fedorak
Journal:  J Crohns Colitis       Date:  2011-09-07       Impact factor: 9.071

7.  The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years.

Authors:  David Cella; Susan Yount; Nan Rothrock; Richard Gershon; Karon Cook; Bryce Reeve; Deborah Ader; James F Fries; Bonnie Bruce; Mattias Rose
Journal:  Med Care       Date:  2007-05       Impact factor: 2.983

8.  Patient-reported outcomes in gastroenterology: clinical and research applications.

Authors:  Brennan M R Spiegel
Journal:  J Neurogastroenterol Motil       Date:  2013-04-16       Impact factor: 4.924

9.  Development of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) gastrointestinal symptom scales.

Authors:  Brennan M R Spiegel; Ron D Hays; Roger Bolus; Gil Y Melmed; Lin Chang; Cynthia Whitman; Puja P Khanna; Sylvia H Paz; Tonya Hays; Steve Reise; Dinesh Khanna
Journal:  Am J Gastroenterol       Date:  2014-09-09       Impact factor: 10.864

Review 10.  The future of measuring patient-reported outcomes in rheumatology: Patient-Reported Outcomes Measurement Information System (PROMIS).

Authors:  Dinesh Khanna; Eswar Krishnan; Esi Morgan Dewitt; Puja P Khanna; Brennan Spiegel; Ron D Hays
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-11       Impact factor: 4.794

View more
  5 in total

Review 1.  Gastrointestinal motility and absorptive disorders in patients with inflammatory bowel diseases: Prevalence, diagnosis and treatment.

Authors:  Luísa Leite Barros; Alberto Queiroz Farias; Ali Rezaie
Journal:  World J Gastroenterol       Date:  2019-08-21       Impact factor: 5.742

2.  Using Twitter to Understand the Human Bowel Disease Community: Exploratory Analysis of Key Topics.

Authors:  Martín Pérez-Pérez; Gael Pérez-Rodríguez; Florentino Fdez-Riverola; Anália Lourenço
Journal:  J Med Internet Res       Date:  2019-08-15       Impact factor: 5.428

3.  Enteric Glia Modulate Macrophage Phenotype and Visceral Sensitivity following Inflammation.

Authors:  Vladimir Grubišić; Jonathon L McClain; David E Fried; Iveta Grants; Pradeep Rajasekhar; Eva Csizmadia; Olujimi A Ajijola; Ralph E Watson; Daniel P Poole; Simon C Robson; Fievos L Christofi; Brian D Gulbransen
Journal:  Cell Rep       Date:  2020-09-08       Impact factor: 9.423

Review 4.  Describing some behavioural animal models of anxiety and their mechanistics with special reference to oxidative stress and oxytocin relevance.

Authors:  Manuela Padurariu; Iulia Antioch; Ioana Balmus; Alin Ciobica; Heba S El-Lethey; Mervat M Kamel
Journal:  Int J Vet Sci Med       Date:  2017-11-07

5.  Potent In Vitro Activity of Citrus aurantium Essential Oil and Vitis vinifera Hydrolate Against Gut Yeast Isolates from Irritable Bowel Syndrome Patients-The Right Mix for Potential Therapeutic Use.

Authors:  Maura Di Vito; Maria Grazia Bellardi; Maurizio Sanguinetti; Francesca Mondello; Antonietta Girolamo; Lorenzo Barbanti; Stefania Garzoli; Manuela Sabatino; Rino Ragno; Alberto Vitali; Ivana Palucci; Brunella Posteraro; Antonio Gasbarrini; Gian Maria Prati; Giovanni Aragona; Paola Mattarelli; Francesca Bugli
Journal:  Nutrients       Date:  2020-05-07       Impact factor: 5.717

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.